KEYNOTE SPEAKER

"Probing Classical Physiology with New Tools: Case Studies in Translational Medicine"

Matthew D. Troyer, M. D.
Senior Director and Neuroscience Leader, Department of Clinical Pharmacology
Merck & Co, Inc.

1:30 pm Anderson Auditorium (C101)

Dr. Troyer is Senior Director and Neuroscience Leader in the Department of Clinical Pharmacology at Merck Research Laboratories. In this role, he is responsible for supervising the early clinical development of promising new treatments for neurological and psychiatric disorders. Matt works with basic and translational scientists during drug discovery and biomarker development to support novel therapeutic programs. In these roles, Matt has been fortunate to collaborate with a broad range of basic scientists, imaging experts, pharmacokineticists, modeling and simulation experts, clinicians and academics. Since joining Merck in 2005, Matt has also contributed to the clinical development of investigational drugs in the areas of diabetes, women's health, obesity and infectious disease.

Prior to 2005, Matt was a member of the Neurology faculty at the University of California, San Francisco, and an attending neurologist in the Parkinson's Disease Clinic. At UCSF he also completed a postdoctoral fellowship in the laboratory of Robert Edwards where he studied vesicular neurotransmitter transporter function and mechanisms of neurodegeneration in Parkinson's disease. Dr. Troyer's clinical training includes a fellowship in Parkinson's disease and Movement Disorders at the Institute of Neurology/Human Movement and Balance Unit, Queen Square, London, and residency at the Harvard-Longwood Area Neurology program where he served as Chief Resident in 1995-1996.

Matt received his medical education at Stanford University in 1992, and graduated from Illinois Wesleyan University with a major in Biology in 1986. His research interests are in the following areas: therapeutics in neurology and psychiatry, neurodegenerative diseases including Alzheimer's and Parkinson's diseases, translational medicine, novel clinical trial designs, central nervous system biomarker development, and model-based drug development.